Form 8-K - Current report:
SEC Accession No. 0001144204-17-007063
Filing Date
2017-02-09
Accepted
2017-02-09 16:15:36
Documents
6
Period of Report
2017-02-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K v458901_8k.htm 8-K 22367
2 EXHIBIT 1.1 v458901_ex1-1.htm EX-1.1 233318
3 EXHIBIT 4.1 v458901_ex4-1.htm EX-4.1 104656
4 EXHIBIT 99.1 v458901_ex99-1.htm EX-99.1 10008
5 GRAPHIC pg1img1_ex99-1.jpg GRAPHIC 12617
6 GRAPHIC pg2img1_ex99-1.jpg GRAPHIC 11029
  Complete submission text file 0001144204-17-007063.txt   404367
Mailing Address 2575 WEST BELLFORT SUITE 333 HOUSTON TX 77054
Business Address 2575 WEST BELLFORT SUITE 333 HOUSTON TX 77054 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671999 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 17587753
SIC: 2834 Pharmaceutical Preparations